MiR126-Mediated Alteration of Vascular Integrity in Rett Syndrome

Why It Matters

Vascular barrier impairment adds a non‑neuronal dimension to Rett pathology and offers a druggable miRNA target to improve brain microvascular health.

Key Takeaways

• RTT iPSC-derived endothelial cells show higher permeability.
• miR‑126‑3p is up‑regulated in MeCP2 mutant cells.
• Elevated miR‑126 suppresses TEK and EDN‑1 signaling.
• Antisense miR‑126 restores tight‑junction proteins and barrier function.
• 3D microfluidic MVN model reveals human‑specific protease profile.

Pulse Analysis

Rett syndrome has long been viewed through a purely neuro‑centric lens, yet emerging evidence points to a compromised blood‑brain barrier (BBB) as a critical contributor to disease severity. The MeCP2 protein, mutated in most RTT cases, is expressed in endothelial cells where it regulates genes essential for vascular integrity. Disruption of MeCP2 therefore reverberates beyond neurons, altering endothelial tight‑junctions, perfusion, and nutrient exchange—processes that can exacerbate neurodevelopmental deficits and limit therapeutic delivery.

MicroRNA‑126 is a master regulator of endothelial homeostasis, fine‑tuning VEGF and Ang/Tie2 pathways that stabilize the vascular wall. In the present work, RTT‑derived endothelial cells exhibited a striking rise in miR‑126‑3p, which in turn repressed TEK (Tie2) and EDN‑1, key mediators of vessel maturation. This molecular cascade led to reduced ZO‑1 and claudin‑5 expression, manifesting as heightened permeability in a 3‑dimensional microfluidic vascular network. Notably, the protease signature differed from mouse MeCP2‑null models, with increased MMP‑8 and altered TIMP balance, underscoring species‑specific mechanisms that only human iPSC platforms can reveal.

Therapeutically, the reversible nature of miRNA modulation makes miR‑126‑3p an attractive target. Antisense oligonucleotides restored tight‑junction architecture and partially rescued barrier function, suggesting that miR‑126 inhibition could complement existing strategies aimed at neuronal rescue. Moreover, the microfluidic MVN system provides a scalable, patient‑specific testbed for screening vascular‑focused interventions, paving the way for precision medicine approaches that address both neural and vascular components of RTT and related neurovascular disorders.